Minimal residual disease: a target for radioimmunotherapy with I-131 labeled monoclonal antibodies? Some dosimetric considerations. Internat Meet Radioimmunotherapy, Oct, 1992, Stuttgart - Herbold, G; Sautter-Bihl, ML; Bihl, H (Strahlenther Onkol, 1993)
(abstr.)